Download Textbook of Therapeutics: Drug and Disease Management PDF for Free - A Complete Guide
in 2008, the united states food and drug administration (fda) approved avonex, a humanized monoclonal antibody targeting the aβ peptide. immunization of an animal model of ad led to aβ clearance and to a decrease in amyloid burden and tau phosphorylation, an effect that was blocked with an aβ antibody [ 52 ]. a subsequent phase 2 study in 101 patients with mild to moderate ad failed to demonstrate a statistically significant benefit on cognitive function or on 3-month change in adas-cog compared to placebo, but treatment was generally safe and well tolerated. the study demonstrated a trend towards reduction in neuropsychiatric symptoms, and a 28% reduction in amyloid plaque burden, but no significant reduction in tau phosphorylation [ 53 ]. the study also showed aβ antibody to be superior to placebo when assessed with a composite measure of global cognition and three subdomains of cognitive function. a larger phase 3 trial (aim-07) is now underway in 300 subjects with mild-moderate ad to assess its efficacy on these outcomes. a group of over 10 human anti-aβ antibodies is in pre-clinical trials and several have shown promising efficacy in reducing amyloid pathology and tau phosphorylation in animal models of ad. some of these have also shown considerable antiviral activity in human trials and thus have potential for combing anti-amyloid and anti-viral/anti-inflammatory activities [ 54, 55 ].
textbook of therapeutics drug and disease management pdf free download
it is clear that there is immense interest in the use of non-pharmacological approaches, and the need to pursue natural and synthetic antioxidants as well as vitamins, herbs, and dietary supplements as adjuncts to drug therapy is evident.